t9n Envet•e ID.. C6Bxf¥)841FT4FgB425CFB955AD957 Registered number: 11943477 Charlty number: 1185091 FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) AUDITED TRUSTEES, REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 111111111111 JDBGH2EO' 111CI312024 COMPANIES HOUSE A10
Env*y ID." c885CC(JU1F74F9W5&5CF89SS? FOLLICULAR LYMPHOMA FOUNOATION (A Company Ilmit¢d by guarant¢•l. CONTENTS Page Reference and administratlv• details of the Company. its Trlee5 and advisers TNst••s' r•port Independent auditors. report on the Ilnancial slalefflents 10-13 Statement of financial activities 14 8alan¢• $h•e¢ 15-16 Ststement of Ilows 17 . N¢t¢$ to the financial stat•Thw 18-32
OCLn ErNdt4e ID.. C6BSC00841F74FW8VsCF89s5A0957 FOWCULAR LYMPHOMA FOUNDAnoN IA company Ilmlted by guarnrf•o1 REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY. TRUSTEES ANO AOVISERS FOR THE YEAR ENDED 31 DECEMBER 2023 Tru$t•os Lord J N Menddsthn L8ty N S MeThJelsohn Lord R l Harrington P M V Thompson AW¢x J J Budey Dr J W siMs Company registered number 1194347.7 . Ch¥rity rtyl$tsr¢d number 1185091 .Réglstèred offlce . New Derwenl Ho 673 Theobalds Road London WC1X 8TA Ind•p¢nd•nt audltors Cw Grow LiThMlwJ Statutory Auditor 69-73 Theobalds Road Lond WC1X 8TA Page 1
Dthn Erwbpe ID. c680DlF74F9u2SscF895SA0gS7 noma FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) TRUSTEES, REPORT- FOR THE YEAR ENDED 31 DECEMBER 2023 The trustees who are atso directors of the charity for the pur)Se5 of thE Companies Art 2¢JA Psent their reportwith the financial statements of the charityforthe Year 10 310e¢ember 2023. The trustees have adopted the prowyons of ACCntIl¥ and Reportir by Charibes_' Statement of Recommended Practice applicabje to charities preparing tTrir acc(wnts in accordaTrce with the IanCIal Ftepwting Standard appli¢aWe in the UK and Reptsblic of Ireland IFRS 1021 leffedi¥E i January 20191. Objectives and activities Our mi55ion is to help those with Follcular Lymphcffla. a currently iVratrIe blood tartr. to live well and get well by finding and fundire the best research to find brèakthroughs that 11 change how we understand and. treat the £onditi¢)n. We pro¥ide Follicular LYMPha fcru5ed infwmion resources for patients and work to ensure patients. vL¥ce5 are at heart of the search for better treatments and cwe. More spttiftally. the Charities objecti¥Es e restricted tothe foll¢bNIry'. To sp)nsor basic translational research to assistin the de1elopent0f bEttertreatmeAtsènd a cure lor Folicular Lymphoma incluin8 spon50rin8 the estsblishment of an international challenge to scientific and clinical re5earcher5 to f¢xus on Arospedb¥ Cure To support the promotion of the 'patient voicÈ". by supporting patient advcxary and education, the develokynent of patient £(xTrmunities and evaluating IhE efficacy ol patient rePted outcomes on current . treatments and yde effects toassist dinioans ar patients. To impro health outcomes by way of st¥nulatin8 research and ewaluation of cOMeMentary conditionsto supplement methcal treatmenL Achievements Gb)I FL 5mmIt.ning Forre5 to Cuwe FL. Tel Aviv, Israel- January 2023 Ovr first international follicular lymphonia tought together a dr¥rse of workl-class lymphoma experts. 5cienti5ts. researchers. and representatiNYs from wortrfs life sciences and biotech bu%nesse5. Wth a shared desire to move the field forward. participants di5CU$5ed opportunities to enhance targeted immunotherapies. The lrnp0rtae of dtveltspirg moknular markers. especially to define high-risk patient5 and the need ftr a deeper understandin8 of how translorrnatiL occws in fdlKular tymphoma. All of which pushes us closer to a cwe. ICML Symposlum 4WIll h T•keto Cwe FLY Lugano. 5wi12erland-June 2023 We were thrilled to host our own satel&"te symposium ai the International Conference on Wlignant Lymphoma. Dr Mitrhell Smith, Chief MedKal OffKer at the FLF. tha1d the session. wh.ch focused on forward-looking presentations lollowed by a di5cuMion with OureXrtparl0f speaker5-. Dr Loretta Na5toupil, DrJe55ica Okosun. Dr Marco Ladetto. and Dr Ari Mdnick. The Stimulati prog¥amme spand from baSbC ts"01&V to h)w to translate those learnings into ihe clini¢ for Fl patients. Laththed Support H.. a dedicated online hub for i117(alS affected by folicular fvphoma. offering edycational and lrfe5tyle reSOues. patvènt Stle% an FL4peofic 0$Sary. and more. The Fcdlicular Lymphoma Foundaiion 417 Finchley Road London NW36J lu@lbelll.wg FR FLNJFWISING REGULATOR 441012Q34178S8J
Dro"g En¥bp8 Iftr. C68K081F74F5SCF895s1D Held educational webinars which We rectived with entgaSM and strow partiopation. underscoring their value to community, and spathng demand for more. Partnefed wllh the Unhersity of Pennsyfvanws Sth¢xA of Ckni¢al Medidnrfs world renowred researchers as part of our Centres of Excellen ICOEI prrpdramme. Hosted a ssmposlwn •t ihe Imernatlonal Q¥nfereKe on Malya•it Lwnpho•na on"What Will il Take to Cwe Follicular Lymphomav which wttre55ed a robust turnout ar¥J 98nifi(antly bDOSted our international visibility to shine a spotlht on follicular IwmphGa. Colabor•ted with The Leukemia & LYry1mo SOC {LLSI in a.stratewc partnership to cure fdl¢cular Iymphorna by eombinirng expertise and resour$. Jointly LI¢bed CURE FL Cyde 2with iL5. iLS-FLF Research UnitedtoCURE FLAward<. luthjing up to 4 research grants totslling up to $3.5rn over 2-3 years. acCe[ating tutbn¢-edge searCh in follicular mphorna. Partnered with The Mart Found•iknn for Rese•r¢h to unite tymFthoma and b'omarker te¢hno104Y experts, advancing novel apwoaehes fc follicular MPhoma. G•thwed insithisfr0in0¥tt7(MIWlents toenharKe ourur¥Jer5tandingtsfbiornarkersand ensure patientvoices are heard. This prowded Invaluab inyehts to inf(m our "0marker dixcwery wogramme fLKu5. Hosled our inawJTrl ldrO1$1 cak dinner raisiw E5CK).LV) to advarKe wr rnissitin of Curi follicular lymphoma. Developed a Bitynarker Protr•mme settofund 1-2awardsai apPr0mate 535Ok eat with a kartrted laynch in 2024. Participated at ASH Ann[ Meetln& wodd's largest haematology conference. engagin8 with currenr and potential partners. and gaining inyghts frcffi the many lymph0ma-fUSed s¥mSia. Strategic report The Follicular lymphoma Ftyjndation is an international efforttofind3ndaccer4te cartd speedthedelivery of preci5ion-based treatments for ihis little-known cancer. The Foundation laurKhed wblicly in November 2019 and ha5 been focused on develowry r(sstratey and laying the framework for a hu8ety exoting prLYdranme ofwork. None of this would have been posglje with(rt the extraordinary 5UPPOrt of the Ivjndreds of indidual$ who have donated to tke FOd30n to help adwe¥e ourgo•l. 3.1 Charitable activities 3.1.1 Strategy Over the course of the year t FLF harnessed itsgtobal networkto develop a strategic apwoath andframework. The Foundation created a wogrammatic plan bèd on pillars.. PiHar l.. The Pat¢nt & P¢ton Me(bcine Programme io harness tl power of paDents and the patient cornmunity in ihe development of (ures and rw wect5ion methoDe approaches Pillar 2-. The Targeted Actelerated Research Programme to in¥est in ontythe most promisir¢ intemational FL search end ¢h"ftieal triats. The Follicular Lymphoma Foundalton 417 Finchley Road London NW3 6HJ nto@IhBIII.tyg www.tPrflll.L 4410120J41785 FR FUNDRAN REGULATOR
ErNekpe10.. C685CCOHIF74FW825&5CF89554tw Foiiicu horna 3.1.2 Partnershlps One of the Foundation's (we working prinapbes is to a¥Thd du&lication and bring added ¥ae to the field by forwng partnershipsto £omplEmentexistire prograrywne¥ drive tter outtomes and ¢ate impaet. Partnerships were estatrjished dyrir8 this ye¥ Vjith fesearch instirutions. oiher non-profits and commercial entities. 3.1.3 Informatlon Provision and Public Awareness Raising The launch of the FLF raised awareness of the disease ith the general put4c and helped link Feopbe Iving with . FL th sources of inforrnation and supporL As part of the launch the Foundati¢)n develowd a new bsite as a trusted uTte of bnfoTmation FL patients and a more dedicated Patient Hubfor FL Patients and families. Tl4"swasthe workl'sfir5t web51tededcated exclusively to Folhcular Lyrnphorna. 3.2 Financial review 3.2.1 Flnanclal positk The Finanoal accwnts fty ihe 12 rnh$ pwiod show a wrplus of £8&832 and charity is well-positioned to increase its actitieS in the e_ 3.2.2 Reserves policy At 31 Oecember 2023. unrestrirted vesers were £1.103.336 and iestrirted reserves tre £161.018. The organisation operateswith limited ¢)vÈrheads. The Trustees have det@mird thatt reser¥es target should be at the le%EI of 3 month5. expected expenditure. Budgeted exnditure in the 2024 finaTKial year is just shy of £1.9m. and the Trustees have sei a targeted reser¥e5 fwre of £5k as at 31 Dember 2023. .The target for reserves in 2024 is to maintn a mirdrmm tovera8e of months. runway. This will ensu that all commitment5 and notices are addre$5ed. the tompany wth adequate time to implement any necessary emergenry measures. Currently. certain prc%rammes. 5wh as PMP. art partiallyon hold dvetofundingconstraints. These prorammes wil be resumed orKe suffi¢nt funding is secufed and inccme streams and tndS the stab"lised. 3.3 Golng concern The Trustee5 Ccder that it is appropriate to prepare tl ffinanoal statements on a gcing concern basis. The eoine concern asyJmption is based on an existin8 business plan and trd8et in Pla.¢0Yeng the period to December 2024. A new 3-year trMJd8et/foreca5t Wa5 drafted. and two annual forecasts planned each Year, expend4ture is micro analysed duriNg these activities whilst Planni long term. In addition, Trustees continue to in%Higate opportunities to enhance the lor%-term sustainatrility of the charity and identify those area5 where the financial krforrnance can be irnproved. with action5 being taken to reduce the deficits. The performance of a 14ghly skilled leam of permanent employee5 demC$trIteS Follicular Lymphoma Foundation's cornrnitment to the operation of the Charity as a 80in8 con¢ern. As a fesult of these lartor5 the Trustees C•der the gn conr basis to b2 appropriate. The Follicular Lymphoma Foundatttsn 417 Finchley Road London NW3 611J ¥Vv.th•lll.¢yg 4UIQI20J41785&1 FR FUNDRAISING REGULAYOR
0¢thn EnvpÈ ID C6B5cCelF74F9SCF89S5AD7 Folllcu m& 3.4 Prlncipal risks and UnrtaIntleS Theirvstees have a dutytoidenbfyand reviewthe riskstowhichthetharttyisexposed atsj toensure awropriate controls are in Pla to pro¥ide reasonabl? a55urarKe against fraud arvj error. The trustees have assessed major risks to wlich the charity15 exposed aThJ are satishEd that SV5terns are in place to mitigate exposure to such major risks. Procedure5 are in place to ensure cCfflpance ith health and safety d staff. volunteers clients. and ¥itorS to the or8anisation. The Charity has ihe appropriate level of insurarKe to meet its obli8atsons iri resped of employees and members of the put4ic and oiherwise has a tYJsiness ctinty plan to cover emtreme even¢ualits. 3.5 Future plans 3.5.1 Plans for the next 12 Months Ouroreus olfo¢us.' Dellverfng 1nN>a¢tthr0h fo¢wed res¢•rth. Closing the gaps in FL rearch and drug devek)pnnt throu8h the dual approxh of the prwsion 'eviden¢e- based. FL inforrnation and in¥t5tin8 in the rnost womiyn8 cufati%e research. Developi rW treatments and cures to FL patients ty creating a pathway with rap¥d 'b2nch-ttrted5ide' developments. Colal>oratlnRwith the be5L Relationships are key to the success of the tharity. We wil map existing and new opportunities for partnerships at an intemational level buddin& on criti(al rektionslup links with medicJ expertg xientific researchers, and philanthropic donS. Growtng fvndralslng kn¢offle. Raising funds 15 essential to ensuring strategic medical progrnmrnes go aPead ènd that we have the financial resources available to carry out the ne55ary scientific research ro find a cure. We strive to maintain and build fundraising streams where possible Whil also eThIng rW or differeni OppOrtune5 to drive fundraisi. 3.5.2'PrecisioD Medicine Programrne (PMP) The Preasion Methone PrOgrae IPMPI hame55 the ptrr of the follicular IphOM? communty to drive research aThJ ¢lini¢ advan$. Aeteleratlni proiress towards a cure Our rnission through PMP i5.to unlock the ptstential of bespoke. pre05iOFt mE(IKine fw FL patien revolvtionising treatment options and propellir8 us closer to finding a cure. 8y leveraging real-world data. includiThA b10Cal information. we seek to p)neer new avenues in FL research and drive Ixopharmaceutical and industry dru8 developrrent. undeandIng unlque bioknfor petsonali5ed iherapv A¢ the core of the PMP is understandin8 each paiient'5 distirKt and utiliyr ihis kno¥¥ledge to predict the m05t effective. tailored therapeutic options. "The Preciyon Meilicine Programffe will be a urque rewce of 8re value w researchers and ultimately to patients. enabling and acceleratiw b"olc8ic and clinical rearch and triats. and uibmately findiry a cure for FL." Dr Mitchell Smith. Chief Medical Officer. The Follieular Lymphoma Foundation 417 FIAleY Road London NW3 6HJ Inlo@iTh¢ltt.OrJ 4410)20J•I78 AEGVLATOR
tkn¢u%¥n Enwc¥e ITr. c6w1B1F74F4Z55cF89S<)gS7 Top research priorities Workiry with partners woddwide.. identified key PMP obRctt4S to adtess urrt follcular MphoM need5'. Vndefstand disease helerene•1¥ Optimise treatment rewmens and seqLn¢in8 Profile and prediu treatment toxiaty tlevelop surrogate endpoints Ifor impro¥ed clinical trial deygnl Generate prospective real-w(ld data Thi5 project hirges on arnasgng the lart reposittyy inforrnatson on FL prowding searCherS. and patients with a newfound understanthng ol the disease. By kVerag1 this v75t datase( we can drive forwwd progress and Iransform the landstspe of FL searCh andtreatrYnt. 3.5.3 Targeted Accelerated Research ITAR) pro£rammes key area for the FLF is therapeutK developftnt initiat$. wlwch can accelerate advanced and tWaratiOnal researeh. To date. the pro8$$ in the treatmertt of FL has been frustratsn8 slow, with litt funding and attention. Our suite of Targeted Accelerated Research ITARI ir¥tiatyves aim to make turatNe therèpes available to FL patients as soon as possib. Our TAR programme5 enhance our progresstowards our rnissioTr by inve5tirE in the highest caltbre research pronN%n8 immediate benefit to the patient ICURE Fl Award51', creating 5trateyc partnerships th top investitators and institutes ar(nd the wcld Icentres of EelIe1xeI.- and ensuring we don't miss out cfi urmque high-risk. h'gh-reward opportunitbES (Opportunity Fundl_ CURE FL Ard5 Prow•mm• The CURE FL Icurative Research to E&rninate Folicular Lyrnphornal Aw•rds pro8rarnme aims to stimuie scientific research into folli(ar. tymphoma-targeted immunotherapy. It fcfuses on iTrnovatNe research that ali8ns wth patient interests and accekrates progresstowards new treatments. A key leature of thi5 approach is prornoting collaboration and fostellre deeper synerÉs amon8 resear¢hers to eAhante capabilities ané advancements in the field. CURE FL AvMrd5 Cyde I Ilaynched 20221 A groundbreaking $2 million prram[r which.funds fJr innovative researchers exploring novel CAR-T cell therapes, or Combinations to enhance immunotheraw as a treakneftt option. The substantial advancernents achie%d thfoughcwjt 2023 could swiilicantjy ath4ance imMunheraPs applied to fol&cular lymphoma. and even other diseases. Meet the 2023 stsntees In collaboration with Milken CSP. we carefully sected propjsals targeting key fc41icular lymphoma reds whi prioritiyng patient intere5t5 and clirrical ap1£atiOn. After a thorLxJgh 5-month review invoknnB experts and patients. we hlenilfied the prcfflisirq PToiects out of 20 worldwide proposals. We are thrilled to introduce our first 8rantees and their exciting research aieas. Each has been awarded up to $500K over Iwo year5. be8innin8 December 2022. This 4nificant imiestffent rnark5 an initral stride toward ¢ur mission. The Follicular Lymphoma Foundation is honoured to support the critical work of the foll¢)wifi8 pK)neerin8 researcher5 who were selerted as the inaugural CURE Fi Award5 grantees in December 2022.. Dr Han$10 Wendel MeTrK>rial Sloan Ketteri ceT Cerrter US.. A rW gnal mechanism IHVÉM/8fLAI abnormal in 90% of FL cases and imp¢ytant in the genesis of FL ha5 been identrfied by Or Wendel and hisgroup. This rnakes HVEMIBTL4 a high-¥ahJe target ycifK to FL CAR-Tcells that attack all 8 cells are anexciiing newtreatmentfcff FL Thi55tudywilluse CAR-T in a different way, to 5pecificalFy affaEk this FL4pecific pathway. The goal is to have a clinic31 trial of these Th)vel CAR-T cells open for patients ty the end of grant perio The Follicular Lymphoma Foundaiion 417 Fift¢hley Road London NW36HJ tnI*+leIlI.or9 FR F.LwJR}.s,G AEGULATOR 441012o34flots
Owsffjn Env10.. C6B5cI)lF74F5&8ScFB8s$A[w7 Folllou Din Drjoshua Brod kahn Sthool of Medne at Mount Sh41 US: CAR-T cells are an excelnt treatment for some patients th FL but do not work for everyone. Dr 8rody, an expert in immunotherapy of tyrnorna. and.his tearn have e¥idence that Wnder ce115 that do not express the CAR-T target are one mechanism of CAR-T resistance. and that they may have a way to overcome tlws. Their study may well lead to a dinical irial of CAR-T gi¥eTh wilh a drug that will enhaKe the killing of these bystander els irnpro¥ing ouicome5 for patients. Drwe in we Comel Medicitr)e US: Or an expert in Iyrnphorna biok4y. along with her clinical collaborators, will conduct trials cOmb'ni epigeretic-targeled EZH2 inhikn'tors with irnmunctherapy (CAR-T or ti5pecifK antibodv2s1. or with apoptOSiS-tar8eted BCL2 inhibtors. Using unique FL mouse models and patieni samples. she i%ill stuty combinations of targeted theraFies with immun0trapy. including impart on both FL B tells and its microenviionment. The plan is to define effective combinioAS tctimpro% trapY in FL Dr Patrlcla Pérez-Galan FuThlatio Oinic a la Reeerca Biofflèda Spain-. Leading this Spanish 8roup with exteny¥e clinscal experience develoFqng CAR-T Cell treatment MphoMa. They will develop new generation dual-targeted CAR-T cells. cells that target not only tymphoma tr115 but also the surrounding mier0enronrnent th3t helps keÈp FL Cells ah"%t. They hope to have a clirrical tria1 otthe best CAR-T ready by the end of the 8rant period. A¢¢derI progress and Impad 8¥ allotaiing alrnosr $2 million o%r two ar$. CURE FL Awards wopel us closer to better treatments and a cure. We aim to elevate follicular lyrnphoma's SIgrfiCance in drug de¥eloprnent and catatyse t4iltsred theraps. Our goal is to brin8 hoFe. opportuniiies. and critical ireatffnt in4hts to patients clinicians. CURE FL Awards Cyde 2 (laundd 20231 We are thnlled io tdlaborate with the Leukaemia & Lyrnphna SoaetylLLSlfor the second rycle of theCURE FL Awards. narne¢J "LLS-FLF United to CURE FL Award<. T(eether. we will co-fund up to fouT research awards. with funding of up to $3.5 million. Thi5 initiative fLu cffi innovi%t SearCh proRtts targeting ¥ cure for follicular lymphcma. The wimary goal is to establish a rational treatment sequence that leadsto curatNe ¢Jrtc(MThes fora broatr group of patÈents. Many submissiL5 have been receibtd and fc4lowing a comprehensi¥e review prttess the chosen re5earcherswill be selected and announced in 2024. FLF Centres of Extelence ICo£l We are cornrnitted to fiyming eolkiborative partnerships with leadine Tesearch inSt[tF0ns through ¢vr Centres of Excellence ICOEI programme. The primary fc$ is accelerating prcgre55 in T-cell-enga8iW therapie5 fc follicular tyrnphoma. S io revdutionise Pient ca. We do this by prLknOtinE knowled8e exchanBe. breakin8down academic barrier5. and fosteriTr8an en¥irOnnTrt corwjucive to rawd acfvancements in clinical care and prc6res5 toward5 3 cure. Sharin¥ knowledie lor rapkl WOBre5S CdlaboraD"on and kn¢)wledRe shafing are inte8ral to the sUc$S of the COE. We stri¥* to break down xademic silos. facilitating an open exchange of infarmationand idea¥ 8yfostering acollaborative environmenL we create the conditions necessary tapid adVanrnents in ¢h"nical Ca for FL patients. Our commitment to sharirg knowledge ensures that Prfe$s is accelerated and impactlul xross ihe entire programme. The Follicular Lymphoma Foundation 417 Finchley Road London NW3 6HJ infoW¢tit FR +441012034TIIU3 REGULATOR
Fo111¢ Curtnteoll Unfvwslty of PennsylnIa Iupennl School of Clinical Medxine Renowned for 0neelIng lyrnph¢)ma research and a kxvotal institutiim iTr CAR-T developt. Our shared proBiamme has intended fundiryl of $5 million 3 years. with aimstOWdlidatetriallinE an appro¥et4 bi-specific a5 a first-line treatment and a revoluti¢)nary newCAR-T at the second bne. Dafia-FaeT Cancer ltsti¢e Internationally acdaimed for Carer research and treatment. Our partnership has enabled the estabh"shment of a COmprenVe prvdramme frKusing on FL incbjdiry the development of cutbngdee technologies to understané. rnonitor and attack FL Sheba Centre and Sour35ky M•JI1 Certr Internationally atdaimed for cancer research and treatment. Our partrer5hip has enabled the establishmebyt of a comprehenyve pr£¥ramrne fcrugnB on FL. inthJdI the ¢kveIoptYTht of (tIngdge technologies to understand. rnonitor and attack FL C Bityarkr0l$¢•¥ery Proyammè Recogni&n8 that the lack crf biarkerS to identify ligh-ri5k patyent5. guide toatmeftt selection or serye as interim endpLMnts to evaluate tre4trnent was a barrier to rawdly developing rw treatments. the FLF embarked on a new initiaitve". The 8iomarker L>scovery Prograrnme. in coUaborètion wth the Mark Foundatlon lor Can¢er Research. This prcf ramme aims to stinwlate research that Mbim eventualfy become state-of-the-art tools and methods for studying multiple kn'olc8ical fxtor5 lomic51 and theii anal.5. iemoving obstxs to successful bKsmarker discov and developNnt and addressirq critical qUestIN in follicular tymphorna. This initiative invc4¥es gaiThng inyghtsfrom leadir¥ intematson31 yientists and experts to co<reate a strategic roadmap and ideniify the most promising pathways to éri4t the follicular lyThphL%na biomarker field forward. Ourin8 2023. the key pr(erarnrne eornponents intluded an investigatLYs workshop. a global patient suryey. and a dedicated patient roundtable di5CUS5ion. The Mark Fourtdation for Cantef Research and the FLF will co-fund through the ASPIRE Award pro¢ram for project5 focused on the de%elopment ol potÈnts31 bi¢%narkers various stages of the patient expernce. This is expected to lay the foundations for traTrslatsn8 thefinthng5 intoclirrical impart th awards antIpated to start towards the end of 2024_ 3.6 Structure. govemance. and management governing documents FLF 15 a private company limr(ed by£uarantee. The company was established on 12 April 2019 under a Mernorandum of Associion whh trMIne$ t objects and pr5 of the charitablE company and 1$ 8fNerwl under its Anicles of Association. The charitable company was rewstered with the Chavity Ccffimlssion 29August 2019. 3.6.1 Decision makwbg The Board of Trustees meets 4 time5 Ptr year and is responsible fv the Strate"C threttion and policy of the charity andfor rnonitoringthe manaBement and outcomesof ServiS. Board members aredrawn frorn a Warty of professional ba¢kgrounds relevant to the work of the charrtv. Th¢ FolltcularLymphoma Found•iityi 417 Finchl*y Aoad London NW3 6HJ inlo@thc tit.Qlg FR PLJNDRAIS,'NG REGULATOR +44(0120Y170583 Iir•O(Wr.IIB5IXil£ff4WOw4lWsl
ErNé D. C685C0D841F74F92s&ScFO9551W? 3.6.2 Statement of trustees, responsibilities The trustees Iwho are also the dirertors of Fdli£ular Lymrthoma Foundation for the pU•Se$ of company lawl are responsible for preparing the Repsxt Trustees and financial StementS in accordance with applicable law of the United Kingdih Accoufits"n8 Stafidards (Uniied Kirvddcffl Generally Accepted Accounting Pradicel including Knan£ial Reportng Standard 102.yhe Financial Reportin6 Stanéard apP1Kab in the UK and Republic of Irelan. Company law fequires trLrtees to prepare finarKial statementsfor each fin¥nci•l Trtar which a true and fair view of the state of affairs of the charitable company and fl the incorn1 resources and apIcatIon of reSr{e$. including the ioMe and expenditure. dthe charitst4e company for that period. In preparing those financial statements. the trustees are requi6 to select suitable acc¢xmlin8 pdioes and then apply them con%stentlv. observe the rnethods and WIrKikeS in the Charity SORP. make jLbdgements and estimaie5 that are reasonabk and prudent_ state whether apph¢ae accountirvd standards have been followed. subj'ertto any.material departures disclosed and explained in tl finanoal YateNntS. prepare the finanoal statement5 on the going corKern basis unless it is inapprowiate to presume that the tharitable ecffiparty wll ¢ontinue in neSS. The trustees ate respon9b fcrf kewn8 proper aCCwnti rettrfd5 wlich di5c105e with reasonable a¢£uracy at any time the finanoal position of the charitaNe company and to enable them to ensure that ihe financial statements comply with the Companie5 Art 2. They a also responsible for safe8uardinB the assets of the ¢haritable company and herKe for taknre reasonab 5tep5 for the pre¥ention and detection c4 fraud and other irregularitie& So far as trustee5 are aware.. there is no rekvant audit infofmation ol which the tharitable company's aud¢tors are unaware,. and the trustees have taken all rteps ihat they Oaht to have taken to make them5elve5 aware of any relevant audit inforrnation and to estab&5h that the auditixs a aware of that infmation. Auditors The audit bUsisS of Hairs Watts London LLPwa5 acquired by Cooper PèrryGroup Limited on 14 November 2023. Haines Watts London Lip has resigned a5 auditor and Cooper Parry Group has been appointed in its place. Cooper Parry Group tsrnited wll be proposed for re-appcxntsnent at the forthcoming Annual General Meeting. Report of the trustees385p-èY'1g a strategic rewt. apprfftd by order of the board of trustees. as the company drettors OA........................ and sgned on the board's beharf by.. Lord J N Mendelsohn-Trustee The Follicular Lymphoma Foundat)rt 417 Finchley Poad Lond NW36HJ W.Ih•lll.w9 +441012034178 FR FIW?RAISING REGULATOR
Doujsign Enyeky ID.. C685COC681F74F9U25cF89s5A9S? FOLLICULAR LYMPHOMA FOUNDATION {A comp•ny limited by guarant••) . INDEPENDENT AUDITORS. REPORT TO THE MEIABERS OF FOLUCVLAR LYMPHOMA FOUNDATION Opinion We have audited the finawal $tstemts of Follicular Lwrphoma Fouftdalion lthè'tharrtable companVI for the year ended 31 December 2023 which comprise the Statement of financial aciwties. the Balance sheet, the Stst$ment of cash llows and thè rdated notes, induding a summary of significant accosjnling policies. The financial reporting framework that has en applied in th¥r preparation 15 applILIe law and United lthngdom Acccwntsng Standards, indlIng Financial Reporting Standard 102 The Finanaal Reporb'ng Slandard applic8tA? in the UK and R8public ol Irdand, {United KiTrJdom Generally Accepted Accounting Practice). In Ouf On)n the financial ststÈmgnts'. give a true arKI fair view of the 5tste of the tharitslle companys alTrdirs as at 31 t)ècember 2023 and of its In{mIng resources aThl a01"0n of resLwr¢es. indudirKJ its income and expenditure for the year then $Ied., hava bèen propedy pr8pared in aCCnce with unit lfjngdom Generally Accepted Accounting Practh'ce: and .havtt been prepared in aCdanCe with the reqUinnts of the Charities hLt 2011. Ba$1$ for ¢)plnkn We ¢ondud8d lr aL•Jrt.in aecordanct vnlh Intemati]aI Stsndards on Auditsng IUKI IISAS IUKII and applicat4e 8w. Our responwbilitye5 under those slandards are fijrther desuibed.in the Audit(xs' responsibilities for the audit of the financial statements section of ryJr report. We are independent of the dritable wmpany in awdance with the ethical requirements that are relevant to our audil of the finanual slatements in the United Kingdom. including the Finanaal ReFrfxI'ng Cojnol's ECal Standard. and we have fulfilled our other ethical sponsitxlities in ac£ordaneè vnth thèsè réquitsments. We bdiève that the audit ewdence we have obtained is sufficient aThY appropriate to pr0? a bays for our c$ni. Conclusions relating to going concem In auditing the finantyal stst8Mts. we have (x)nduded that the Trustees. LLse of the going ccfficern bass ol accounling in the preparation of the finan(4al staternents is appropriate. Basad on the work have performed. have not Identiffi any malwial uncertainties reting to event5 or conditions that indivklualfy or cc41e¢'vdy. may cast sgnificant doubt on the tharitsble companys atr¥'lity to nts'nue as a gryng cry)(%m fr)r a pen"r)J of at least ts¥elve monlhs from vthen the finanaal statements ale authorised for issue. Our r•sponsibi'lil'es and the respowbilities of the Truees wth respe(* lo grjng cfficem are described in the levant 58diMs of this (Èrtht Page 10
DcoJsn En¥eW itr. ce85CODM1F74F9M25&5CF8955AW7 F(LIcULAR LYMPHOMA FOUNDATION (A company limit¢d by guardnt••l INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF FOLLKULAR LYMPHOMA FOUNDATION ICONTINUEDI Oth•r Inlomiatlon The other infcmaton ¢omwsès thè infomiation induded in the Annual rewt other than the finanual slatements and our Auditors, reFk)rt thereon. The Trustses are rtrspongble for the other information contain&J within the Annual report. Our ow'nion on the finanual staterrents doe5 noi ¢over thè othèr inlormation and. except to the extent othemise explicitly $tat8d in our rep. we do not express any form of assurance con¢lu5ion thereon. Our responsibility is to read the olher inlormaknon aThJ." in doing so, cOnser whether the other information is rnatertally inconsistent with the finanoal statements or ¢)ur kntrAèdge obtained in the cojrse of the audit, or otheise apar$ to bè materially misststed. If we entty such material inconsistencies N aN)3rent material mi55tatements, we are required to detemlne whether this gives rise to a material misstatement in the financial statements themsdves. 11. bas on thè wixk have performed. we condude that there is a material rnisstatement ¢)f this other information, we afe required to report that facl. . We have nothing to report in this regard. Matt•rs on whlch we ar• r•qulr•d to report by Wè haw nothing to rem in Pect of the fdbwrrfJ matters vkre Ihtr Charities IA¢wJnts and RePs) . Regulations 2008 reqLMres us to report to if. in our ¢¥In.. the inlomwb.on 9iv¢n in the TnbSt••s' reimxt is inconsistent in Y material respect the financial slalements.. or sufficIt acCoun'n'recOrdS have nol been kepL the finanoal ststements are not in agrnent the aczwnting recxd5 and robJms'. or we have not received all ihe Informati and ewanations we require our audit. R•spon$lblliti•s of Irust••s As èxplained more fully in the Trustees. responsitmlffjvs statement. Ihe Trustees Ivtho are also the directors of the ¢haritsble company for the wrposes ol company law) are respOne for the preparation of thè financial statemenls and for beity salisfied that they a tru¢ ar¥J fair view. and for such intemal control as the Trustees determine is necessary to enatle the weparatKm ol financ1 staterrEnts that arè frè• from material misststèm•nt. whether due to fraud or err. In preparin9 the ffinanual statements, the Trustees are responsiNe ts assessing the carilatAe conw8nYs atslity to continue 8$ 8 g(Mng ¢$m. ¢Jisdosing. as alCae. matters rdated to wng cOrn and using the going ¢oncem basis of accounting unless the Trustees eitlw intsrKI to liquKJate the charitsE& company or to cease cperations. or have no realistic altemative but to do so. Pap11
DcoJgn Envelope ID.. effjBSCCQ841F74F9B425&5CF89s5jgS1 FOLLICULAR LYMPHOAIA FOUNDATION Company limited by guarantee) INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (C014TINUEDI Auditors. responsibllltlos for the audlt of th• financlal stat•m•nts We have been appc4nted as aLMJitof under section 144 of Iho Charttses Ad 2011 rep)rt in aco)rdance thè Act and rglevant wulati$ nwe or having effeclthereuryjer. Our objectives are lo otrAain reasonable assurance atJut whether the financial statemants as a whdo am fr&& from material misstslemenL whether due lo fraud or error. and to issue Auditors, rèwt that in¢lud&s our opinion. Reasonable assurance is a high lèvd of assurance, ixrt is not a guarantee that an audrt ndUcted in accordance wrth ISAS {UK} will aayS detect a matwial misstaternent when rt exists. Misststements can arise fr¢)rn fraud or error and are considered maten'al if. individually or in the aggregate, they could re8sonaUy be expected to influence the eC(0M1¢ de(i%ons of usws tak•n on thè bass of th$$¢ ffinantsal ststements. Irregularits'es. induding Iraud. arè instances of non-compliance laws and reyulations. We design procedure5 in line ¢Jur rSp151mIits"?, ouuineil aLw. to dete(X material misstatements in reSpt of irregularities, induding fraud. The extent to which our procedures a capable of det•th'ng irregulariti$$, induding fraud 1$ detailed bdow.. We gained an undeistanding ofthe legal and reglAa framwth al¢ale to the c¥ynpany and the industy in whiGh. it operates, and rSIdered the risk of acts by the company that were contrary to applicable laws and gulalions, incltxling fraud. We discussed with the Directors the 1cleS and proc&dures in place regarding compliance wth laws and regulations. We discussed arrKxost the aL¥Jrt team the identifièd laws and wulations. and remained alert to any indicab(YbS of n-comlance. During the audit we f(xusse(I laws arKI regulalions which cwkj a9)nablY be expected to give rise io aterial misststement in the finanoal statements. induding. txrt not limrted to. Ihè Companies Act 2006 and UK tax legislation. O¢Jr tests induded agreeing the fmancia Ststement th$dosures to undety'NJ SUprtirj doujmentation and ènquiries with managament. Our rUle5 in relatr'on to fraud incIjed but were not limited to". irquires of management wheth8r they hav8 any knowledge of any actsjal. suspecled or allegeJJ fraud. and discussons amongst the audrt team regarding risk of fraud such as 0pFQrtunes for fraudulern manipulab.on of finala1 5tatemenls. We determined that the principal risks rglated to P95ting manual j(wmal enln.es to manipulale financial performance and managernent bias through judgements in accounting esb"mates. We also addssed the risk of managom&nt OV8rride of interrial controls, induding testing journals and èvaluating whèthèr thw• was èviden¢e of bias by the directors that represented a risk ol material mi&8t2tement to fraud. Because of the inhert limital¢ons of an audiL th8r& is a risk that we wll not det¢¢t all irregularities, induding those leading.to a mat•ial misstatement in thè finanoal slatèmonts ty n¢)n-compliance with regulaty'on. This risk in¢re8ses the more that Complianctr wlh 8 law or regulab.ort is remved from the events and transactions reflected in the finCial statements. as we wll be less likdy to become aware of instsn¢es of non-cmplInc?. The risk is also greater regarding irregularitie$ 0rnng due to frau¢J rather than error. as fraud involves intenbonal ¢oncealment. ftygery. ccllu5iry). omis5iM or misrepre5entslicffj. A further description of Jr Tespon&txlibes for the aJit of the finanaal statements is Ic¢ated on Flnancaal Reporting CoJncil'$ Weble at.. ww.frc. .ukJaLJitorsres nsibil.s. This tjescripb'on forms part of our Audilors, report. Page12
FOLLICULAR LYMPHOMA FOUNDATION {A company limited by guaranteel INDEPENDENT AUDITORS. REPORT TO THE IAEMBERS OF FOLLICULAR LYMPHOIAA FOUNDATION ICONTINUEDI U$0 of our rnport This report is made solety to the Companys members. as a body. in accordance wrth Part 4 of the Chanties (Accounts and Repts1 Regulations 2008. Our audit work ha$ been undertaken $0 that we might state to the charitable Cornpanls members those matters we a required to state to them in an Auditors. repk)rt and for no other purww. To the fullésl extant pemiittèd by Law, we do not accept ¢y assume respc$1bljity to anyone other than the charitstle Company arKI its mernber5. as a LKMJY, for our audit w(k. for this report. or for the nKJns we have fornd. Jane Wills ISenk¥r Stabjtory Audlttsr) for and on behalf ol Coop•r Parry Group Limttad Ststutory Auditor 69.73 Theobakls Road Lcind WC1X 8TA Date.. 9 Septe[ 2024 Page 13
[NxSn ID.. C6B5CODM1F14F9U2**F895SND957 FOLLICULAR LYMPHOMA FOUNDATION {A COMpY Ilmitsd by guarante•} STATEMENT OF FINANCIAL ACTMTIES (INCORPORATING 114COME AND EXPENDITURE ACCOUNTJ FOR THE YEAR ENDED 31 DECEMBER 2023 Restricted Unre¥tTl¢t¢d fund$ funds 2023 2023 Total funds 2023 Tatal fund5 2022 Note Incom• from: Donations and legacies Investments 295,857 1.766,378 6,419 2.062.235 6.419 2,184.639 1.619 Total Incom• 295,857 1.772.797 2.068,654 2,186.258 Exynditllf• On- Raising lurKI$ Chants$ ath"wts•s 251.245 1.587.158 251,245 1.728,575 330.452 2,079.711 141.417 Total •xp•ndliur• 141.417 1.838.403 1.979,820 2,410.163 Net IoMe1(xPQnd1lUr•) Transfers beeen fvnds 154.440 22,979 (65,6061 122,9791 88,834 1223.9051 14 Net movement in funds 177,419 188,5851 88,834 1223,9051 R•eoneilialion of lunds: Total funds brought forwa Net mov•m•nt in bJIS (16.4011 177.419 1.191.921 188.5851 1.175,520 88,834 1,399.425 1223.9051 Total fvnds ¢arried forward 161.018 1.103.336 1.264,354 1,175,520 continuing aperatlons l irKome and experKlJtfft has arisèn from eonlinLmg actvjbes. Page 14
OwJ$ign ErNdep ITr. C689COW1F74F98425W8955fvD957 FOLUCULAR LYMPHOMA FOUNDATION IA company limited by guante¥ REGISTERED NUMBER: 11943477 BALANCE SHEET AS AT 31 OECEMBER 2023 2023 2022 Not• Flx•d a$séts Tangl8"aSSetS 4.999 7.033 4,999 7,033 Curr•nt a$s•ts Debtors Cash at bank and in hand 12 83,846 1.287,372 57,766 1.381,442 1.371.218 1.439.208 Creditors: amounts falling due year 13 (111.8631 1270.7211 Net curr•nt ass•ts 1.259.355 1,168.487 Total ass•ts l•$$ ¢urrent Ilabi116•s 1.264.354 1,175,520 N•t a$$•ts •x¢luding p•n$lon aswt 1.264.354 1.175.520 Total net a55ets 1.264.354 1.175.520 Ch¥flty funds Restricted lunds Unwtricted funds 14 167.018 1.103.336 116.401) 1.191.921 14 Total fvnds 1,264.354 1.175.520 The ent¢ty was entsed to e¥err¢kn" from audit uTrJer secl'on 477 of the Compwies Ad 2006. The member5 have not rèquired the entity to otlain an aJit for the'year in queth.on in ac£Ndanct wrth sectton 476 of the Companies Act 2006. However. an 8JIt is in accrydance wth Secti 144 olthe charib.es Ad 2011. The Trustees a¢knowlwJge their respcmsibilities for cOmn9 the réquirements of the Act wth respect to accounting records and preparathcffl of financial statements. The finanryal ststements have been prepared in acc(wtsn¢e wilh Ihe fMwsion$ applica18 ¢0 entsbes Subj to . the small companies regime. Page 15
Doru5yn Env*pe ltr. scoO81F7-4F9825CF8g55AD9S7 FOLLICULAR LYMPHOMA FOUNDAnON (A company limited by guarantee) REGISTERED NUMBER: 11943477 BALANCE SHEET ICONnNUEDI AS AT 31 DECEMBER 2023 The financial statements were approved and aulhori5th1 for issue by fv.Trustees and Tred cm thar behalf by.. Lord J N M¢ndel$ohn Trustee Dats.. 30-08-2024 Pa9e 16
Dty)J5w3n en¥dcye ID.. C685COD841F74F9U25CFaVA4t . FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guardnteel STATEMENT OF CASH FLOWS FOR.THE YEAR ENDEO 31 DECEMBER 2023 2023 2022 Cash tlow$ from operatlng •¢tl¥ities Cash gerat8d.frn operalKrf)S 183.6401 {48,4531 C•$h ftow$ from inv•sting aclivltl•s: Purchase ol tangible fixed assets Interest received 14481 6.419 14.61)01 1.619 N•t ¢•$h (u$¢d invprovlded by in¥sling activftl 5.971 12,9811 Change In cash and cash equivalents in the year Cash and cash equivalents at thè baginning oftht year 177.6691 1,365.041 {51,4341 1,416,475 Ch and c$h ¢qulv4l•nts •t th of the year 1,287.372 1,365,041. Page17
cwsion Enykn ID.. c685coalF74F9FA35FO955 FOLUCULAR LYMPHOMA FOUNDATKIN IA MpanY Ilmitsd by guarnntso) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 A£counting pollGi•s 1.1 Basis of preparation of fin•neial stslemènts The finala1 statements have been wepar&J in aordartt wrth the chariti.es SORP (FRS 1021 _ AcCn'n9 and Reputng by Charibes.. Statèment ol Recommended Pracfy'ce applicable to charib.es preparing thwr aco)unts in accordance the Financial Rawting Standa. applicable in the UK ant1 Republic ol Ireland IFRS 1021 leffective 1 January 20191, Ihè Finanoal Reporting Standard aptAicalJe in the UK and Rewblic of lrtland IFRS 1021 aThJ the C¢ryanies Act 2006. The financial slatements have been prepare(J tJn(Jer Ihe hiStl¢al cost convenbon. Follicular Lyrriithoma FoundatKM is a private'company limited by guarantee. a wistered charity. 12 Going Concern The finanoal statements have been prepared on a going concem basis. Thè Tnjstees have reviewed and considèred relevant information. including the annual budget and fvbJrg cash flows in making their assessment. Based tlwse assessments. and the ujrrent reswrce5 available, the Tru$tèès have conduded that they can cmtinue to adopt thè going eoncern basis in preparing the annual report and acCjnts. 1.3 In¢om• l irKome is reccJnised the Company has tIement to the income. it is probable that the inujme wll be received and the of income recei¥alJe can be nwsurJ reliaNy. 1A Exnd6tr¥ ExpeTrJituTe is recognised once therè is a 1•9al or constructive olgaOn to trarhsfer econorDiC benefrt to a third party. it is probable that 8 transfer of ew)omic beneffts wll be required in settlernent and the am(yJnt ol the otrAigation can be measured rdiably. Expenditure is dassifièd by activity. The costs of each a¢tsvity are maje up of th& totsl ol direct cmts and shared costs, induding support costs involved in Y[r"n9 èach ath"Mty. Direct costs attritMJtable to a single acty'vty are 811oe2t8d diréetly to that actiwty. Shared costs whith contn"txrtè to ffl8 than one activity and support costs wthich are nol attributable to a yngle aCty'ty are 8pprytred between th08e at'vib"es on a basis consistent with the use of resources. Central staff costs are allcKated ffi Ihe basis of ts.me spent, aThJ depreciation" charges 4localed on the of tl asset'$ use. Expenditure on raising funds indudes all expendtture 4wrrèd by thè Company to raise funds for its "charitable wrposès and indudes costs of all fundraising actIveS events and nori-charitable trading. Expenditure on tharilable actiwthes is on iredly uThJ$rt"ng the activities which fijrther the C(YnpanYs obJ"8¢tives. a$ well a$ any assoaated costs. Grants offered subject to c(dOn$ whi¢h havè not bèan mèt at the year end date are noted as ¢ommitment but not a¢¢rn¢d as eXpdthre. Gov•mance costs Govemance costs indLKle ¢osts of the preparati and exanall0 of the stslutory accounts, the costs ol trustee meetings and the cost ofany189al th"¢0 on govemanee matters. Page 18
Dopjggn Envei¥10 C6B5cOD&8IFT4F9942SB9s5)957 FOLUCULAR LYMPHOMA FOUNDATION IA company Ilmlt•d by guarante•l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 A¢countlng pollcl•s (contlnued) 1.5 Tax•tion The Company is cLSide to pass the tests set OLrt in Paragraph 1 Schedule 6 of the Finance Act 2010 and therèfore rt meets the deffinith.on ol a charitable company for UK corporation tax purposes. Accordingly. the Cornpany is potenty'ally exempt from tsxation in respert of income or ca"ts1 gains received within categories c4Jvered by Chapter 3 Part 1101 the Ccwation Tax Acl 2010 or Seth"on 256 of the Taxabon of Chargeable Gains Act 1W2. to the extent that suth income or gains are applied exdusivety to chartstje WrSe5. 1.6 Tanglble fixed assets and depredallon Tangible fixed assets are inrtially recc3nised at After reccgnition. under the co$t modèl. tangible fixed assets are measur•1 at cost less acajmukqled ttepreual'on and any accumulated impaimènt l¢Jsses. All o)sts Incur to bring a laWe fixed asset into its intended working condition should be indu(Jed in the'measur8ment of cost. Oepreciation is charged so as to.allocate the cgst of lawlje fixed assels le55 their residual valu• over the¢r estimated useful lives. using the straight-line rnethc(l. Depreciabon is prow¢Jed on the fdkm.rg ba&s'. Computer eqUiprynI 1.7 0•btows Trade and other debtor5 are recognised at the setuement amount after any trade discount offèrèd. Prepayments are valued at the arrount prepaid net of any trade disoyrnts due. 1.8 Cash at bank and On hand Cash al bank arKI in hand indudes cash and short-temi highty IiquTfl invèstsn•nts with a short maturty of three months froffl Ihe date of aul51¢)rt of the depo*t Of Similar actnI. 1.9 Uabllllies and pm¥lsi¢)n$ LialItieS ar• reccgnised when thwe is an olgati( at the BaLlre sheet date as.a sum of a past èvènt, it is probablè that a transfer of eCIomiC tenefit wll be required in setuement, and the amunt of the settlemenl can esb"nKgte(I rdialty. LIalItieS are r¢¢(yJnis¢d at the amount that the Compony anticipates it wll pay io setue Ihe debt the amount it has receive(1 as advanc payments for thè 9otyJs or s•tMCaS it must provide. Prw&¢)ns Are measured at the best estimate of the amounts required to sethe the obligation. Where the effect of Ihe time value of m¢)ney Is matèrial. thè prowsK)n is based the presènt value of thosè amounts, disCjnIed at the pre-tax diso)unt rate that reflects the risks specific to the liability. The unwnding of the di$count is r8CC•Jnised in the Statement of finanual actiMtias as a ffinance cost. 1.10 Flnanelal knstrum•nts The Company onty has ffinanaal assets and finan¢ial llats18S of a kiThJ that qualrfy as basic financial Instruments. 8asi¢ finaniial instrurrents are inilialty renIsed at Iran$action value and subsequently measured at Ihw"r selvement value wth Ihe eXrbOn of bank loans whith are subsequently méasured at amortisèd cost u&ng the effective interest mèth(¥J. Page 19
Owsign Envdcy ID." C6B5COWIF74FW25&5CF8955hD957 FOLLICULAR LYMPHOMA FOUNDATION {A company IlmSted by guarantee) NOTES TO THE FINAMCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Aeeountlng polld•s Icontlnued) 1.11 Hlro pur¢haso and leaslng commltments Rentsls paid under operaling leases are charged to the Statement of FinancAal Adivities on a straight lin¢ basis over the period of Ihe lease. 1.12 Pensions The charitsblè ttjmpany operates a defined txtn.buli0n penon stherne. Contsibutions payable to the charitsble compan15 pengon h¢m are thargwl to the Ststement ol Financial Activitiès in the peri(J to whth they rdate. 1.13 Fund a¢¢wntlng General lunds are unrestricted funds whith are available for use al Ihe di5creb.on of the Trustees in furtherance ol the general c4'ectives of the Company and have nol been designated for oth$r purpcjses. Restrict•Y funds a lunds wlM¢h a to btr in ac¢(Ydan¢e th spg¢ifi¢ f0stricti$ imposed by donors or which have been raised by the Cornpany for parknojlar purposes. The costs ol raising and administenng such funds a tharged against the specific fund. The aim and use ol each reslricted fund Is set ojt in the notes to the financial statements. Investmenl irK)yne. gains and IrAses a alo¢at1 to th$ appropriate fund. 1.14 Slgn5ficantJudgement and estimates pparatiCAl of the financial ststeffthts requires management to make significant judgements and estimales in deiemiining th8 cal.j amcyjnts ol accruals and delerTed income. Management makes aSSMpon$ of the effecls of uncertain U[e events those a55ets and liabilib.es at thè balan¢ . sheet date. The managemenys estimates and assurnw.r5 are based on hi5tori¢al experiénctr and expectstion of luture events and are revivw&J pencJically. This disdosure exclud85 uncertainty over futu events and judgerrnt in respect of measuring finanaal inslnjments. Management do consider there lo be any malerial judgerywts or gsts"nwtion and un¢wtainty r8quiring isdosure. Crltlcal acmuntlng estimates and of Ju(tgm•nt Estirnales arKI judgrnents are conth"nualty evaluated are ba$ on historical ayrienc8 and othèr fadors. indudirvJ expectati$ of tuture events that are believed to btr reasonablè undèr thè tircumstsnctt. Critical accounting estimatss a5sumpthons.' Th& Cornpany m*e5 e51imales and assumpb'ons ctyceming the fultsre. Th$ re$Llting accounting ests'mates and assumptions wll. by definitK)n. seldom equal Ihe relaled actual result5. The e$ts"mates and as$umpts"ons that ha a significant nsk of causing a material adjustment to the carylng amounts of assets and l¢abilities within the next fmancial year we di>>Jssed b81ow. Page 20
CwJswJn 10." C680081F74F3s&5cFa95SAD9S7 FOLUCULAR LYMPHOMA FOUNDAnoN IA company Ilmlted by guaTrnt¢e NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOED 310ECEM8ER 2023 Incom• froffl donat•ons and legxies . R•strict•d Unr•strlct•d fund$ funds 2023 2023 Total funds 2023 Oonalions 295.657 1.766,378 2.062,235 UnT•Strlctsd funds 2022 Totsl funds 2022 Donalb)ns 2.184,639 2.184,639 InveslJn¢nt incom• Unr•strlcted funds 2023 Totsl funds 2023 Deposit account inlerest 6.419 6.419 Unrestrictsd funds 2Q22 Total funds 2022 D8post account interest 1,619 1.619 Page 21
Dwvan Ert¥ey ITr. C685COt)M1F74F9&82*5CF8955AD957 FOLUCULAR LYMPHOMA FOUNDATIOM {A ¢omp•ny limlt•d by guarant••) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER2023 Exp¢nd1tU on rni$ing funds Fundralslng trad5ng •xpense$ Unr•strl¢ted funds 2023 Total lund$ 2023 Wages and salaries Event costs 116.082 9).098 1.091 138 1.357 42.479 116.082 90,098 1.091 138 FuThJraising fees IT and suppyt costs Market'ng and Comrnunirations . AlocalK¥I of ger41 ovtrrheads 1,357 42.479 Totsl 2023 251.245 251,245 Urtr¥strict•d fvnd$ 2022 Total funds 2022 Wages and salaries Event Co81s Fundraising fees IT and 5Uk)PQrt ¢osts markety.ng and CommLmications location of overheads Con5vltsn¢y Travel Investmenl management costs 86,929 14,220 12,950 25,404 8,233 69.836 99.069 1.926 11.887 86.929 14.220 12.950 25.404 8.233 69.636 99.(9 1.926 11,887 Totsl 21)22 330.454 330.454 Page 22
DO5] En¥ekye10.. CWCI)W1F74F9M25&5CF895SAD957 FOLLICULAR LYMPHOMA FOUNDATIOM IA ¢ompany limited by guarant••) NOTES TO THE FINANC STATEMENTS FOR THE YEAR ENOEO 31 DECEMBER 2023 Analysls of •xp•ndlturn on charltsble aclivlli Summary by fund typ• Restricted Unrestricted funds lunds 2023 2023 "Total 2023 Dirèct costs 138.682 2.735 1.484.rJJ1 103.157 1.622,683 105,892 Suppcrt costs T¢)ts12023 141,417 1,587.158 1.728,575 ' R•striet•d Unr•strfct•d funds funds 2022 2022 Total 2022 rA'rect costs . Suppyl o)sts 422.725 1.153.912 503,074 1,576,637 503,074 Total 2022 422.725 1,W,986 2.079.711 nalys1$ of •xpondityr• by a¢tivlll•s A¢tlvlfj*$ undertakon diredy 2023 Support costs 2023 Total funds 2023 .rect costs Support costs 1.610.383 12.300 105.892 1,622.683 105.892 Total 2023 1.610,383 118,192 1.728,575 Page 23
D>jgn Env10. C6B5CCQMIF74F9U25CF8955AD957 FOLLICULAR LYMPHOMA FOUNDATIOM IA company limlled by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Analys1$ of •xp•ndltur• by activitiH {¢ontlnu•d) Activitie und•rtak•n dlr•elly 2022 Support eosts 2022 Total" lunds 2022 Oirect C4)51s Supwt costs 1.560.335 16,302 503,074 1.576,637 503,074 Total 2022 1.560.335 519,376 2.079,711 malysl8 of support costs Govomane• Costs . 2023 Support Costs 2023 Totsl funds 2023 markth.ng and Communicab"on$ Wagès aThJ salaries Consultancy fees IT and suppcrt costs Travel and accomfflfyjation Entertainment Bank char98s Computer o)sts Postsgè and stab.0ry Administrativè expénses Legal 8xp8nses De5xlat.0n General expenses Orrab"n9 lease expenses . Event 515 Stsff training Recruiiment cx)sts Alocation of general ovetheads Foreign exchange losses Govemance costs 34.588 185.981 36.242 15.180 339 122 34,588 185.981 36.242 15,180 339 122 1.583 15.4 572 4.003 1.421 2,483 1.583 15,496 572 4,003 1.421 2.483 32,004 32.004 3,657 3,657 16,169 16,169 1267.7961 I267,7) 22,284 22.284 12.31KI 12.300 ' Total 2023 12.300 105.892 118,192 Pa9¢ 24
Ow¥ign ErwdopE ITr c6BScOD841F74F9&825&F8gSSAD9sT FOLUCULAR LYMPHOMA FOUNOATION IA e¢)mp•ny limitèd by guarant••) NOTES TO THE F114ANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEMBER 2023 Analysls ol •xpendltur• by actMtl•s {contlnu•dl An4ty$i$ ol support ¢osts l¢ontinuedl Govarn¢¢ Costs 2022 Support Co$ts 2022 Total fund$ 2022 Marketing and Communi¢2thons Wages and Sakries ConsultaiKy . Travel and a¢¢ommcrtlation Bank charges Computer $ts Posts99 $tsts"onery Administrathvè 8xpse5 L8gal èxp.8nsos Deweoation . General expenses Operating lease c¢Jsts Recruitment cosls locath. of.general overheads Foreign exthange gain Cure FL management ¢))5ts &)vefnan¢e w5ts 94.417 167.393 225.621 10 94.41T 167.393 225.621 10 1.119 13.811 1.175 41.689 829 1.119 13.811 1,175 41,689 829 3.263 153 24,070 4,384 222,6441 184,5101 232,294 16,302 3,263 153 24.070 222.6441 184,5101 232.294 - 16.302 Total 2022 16,302 503.074 519,376 Audltors. r•mun•ratlon 2023 2022 Fees payable to the Cofflpanys auditor the audit of Ihe Comp8nl$ annual accounts 12.000 15.056 S costs The average nun*erof persms employed"bythe Company thring Ihe was as fdlthvs.. 2023 2022 No. ErnoYeeS P4e 25
Envdcye ID.. C6B5C(YJ&81F74F9B42F8955AD957 FOLLICULAR LYMPHOMA FOUNDAnoN {A company Ilmiled by guarnntsel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Stsff ¢o$ts {e¢ntinu¢d) The number of employees ¥th05e benefjts (exduding ernoYer W51 wsts) exceeded £.CK) was.. 2023 No. 2022 Ho. In the band £60.001- £70.{X) In the band £80.001- £w.r . In the band £W).IX11- £100.fA)O In the band £100.LX)1 - £110,OCQ In the F)and £200.LX)1 . £230.0(M) 10. Truste•s' remuneratlon and expenses During the year, no Twees rtteiv8(1 y renwnwabm or othor b¢nefits12022 . £NILI. Donatlons from Trusl•¢s During th8 pariod. thè totsl aggregate aTh#yJnt of urfttlricted donations from Trustees was £71,7rxi 12022.. £9.OLKJI During the year ended 31 December 2023. no Trustee expenses have t)een incJm¢J12022. £NIL). 11. Tangibl• fix•d ass•ts Compuler •qulpment Cost or valuation At 1 January 2023 Additions 14.816 448 At 31 December 15.264 D•pr•¢latlon At 1 January 2023 Charge the year 7.783 2,482 At 31 0mber 2023 10.265 Pa99 26
Envebpe10.- C885CODO41F74F92s&scF89S7 FOLLICULAR LYMPHOMA FOUNDATION (A company limited by gu¥rnnts¢ NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 11. . Tanglble flxed ass•ts {¢ontinU) Comput•r equipment Net book value Al 31 t)ecember 2023 4,999 Al 31 Oecember 2022 7.033 12. Debtors 2023 2022 Duo wlthln on• year Traje debtors Prepayments and acc incwe 73.256 10,59) 50,OTrJ 7,766 83,846 57.766 13. crlIorS.. falllng du• t*1th5n one year 2023 2022 . (Mr(Iraft due to negative restsicted bjnds Trade ¢redito Other taxation and Slar secJJrity Pensim fund loan payable Other creditors Acwals and defeed incc¥ne 16.401 211.984 23.579 850 72,972 24.723 1.580 71A 17,201 12,588 111.863 270.721 Pa99 27
ciyjjsyn ID. C6B5COD841F74F9U2WCF8955AD957 FOLUCULAR LYIAPHOMA FOUNDATION (A company1Smited by guarJnt•el NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 14. Stat•m•nt of lunds stst¢m•nt ol fund$. ¢urr•nt year Ba1ce at 31 D•¢•mb•r 2023 Balance at 1 January 2023 Transf•rs Inlout Income Expendltur• Unr•str6eted funds Unrestn'cled fuTrJs 1.191.¥21 1.TT2.797 (1,838.4031 122.9791 1,103.336 Balanc• at 31 De¢mber 2023 8•laneè at 1 January 2023 Transler$ inlout .kn¢om• Expondltur• R•strfet•d lund$ Maurice Wohl Charitable Foundation - towards Cure FL research ma Foundatson Cancer Researth - towards Cure FL research 8I(nVt Intemat'onal AB & NovartiS-- towards Lugano event Abbvie Ltd- tth¥ards Cure FL resear 116.4011 (93.4131 90,186 70.832 70.832 20.275 (38.4491 18.174 4.750 19.555) 4.805 116.4011 295.857 1141.417) 22.979 161,018 Total of funds 1.175.520 2.068.654 11.979.820) 1.264.354 Page 28
FOLLICULAR LYMPHOMA FOUNDATION {A ¢ompany limitèd by 9ua¢ants•) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2023 14. stat•mont of funds l¢ontinu•d) stst•m•nt of funds . prlor year Bal•nu at 31 DK•mb•r 2022 8alane• al . 1 January 2022 Expenditure Unrèstrlcl•d funds Unresfncted lurwJ5 1.399.425 1207.5041 1.191,921 R•striet•d funds Maurice Wohl charita¥ FCwnd3ti- toAtaS Cure FL rèsearch 116,4011 {16.4011 Total of funds 1,399,425 1223.9)51 1.175.520 15. Summary.olfund$ Summary of funds - current year Balancè at 31 D¢¢èmber 2023 8alanu at 1 January 2023 Transfe Inlout In¢ome Exp¢ndllur• . Genèral lunds Restn"eted lU1S 1.191.¥21 (16.4011 1.772.797 295.857 11.838.403) {141.4171 122,9791 1.103.336 22.979 161.018 1.175.520 2.068.654 11,979,B201 1,264,354 Page 29
Envdope ID". C885C00&81F74F9WF8g5S? FOLUCULAR LYMPHOMA FOUNDA0 {A ¢ompany limitsd by guarnnt••l NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 15. Summary of fvnds {contlnued} Summary olfvnds . prior year Balan¢• at 31 D•¢èmb•r 2022 Balance at 1 Janu•ry 2022 ExnditUre. Designated fLmds Restricted fuThJs 1.399.425 1207,5041 116,401) 1,191.921 116,4011 1.399,425 1223,9051 1,175,520 16. Analys1$ of nat assèts b•ta•n funds Analysis ol net assets belween (unds- ¢urrent yÈ*r R•std¢tod Urtr•$tri¢t•d funds lunds 2023 2023 Total fund¥ 2023 Tangle ffixed assets Current assets Cr&Jitors due vnthin cffle year 4.999 1,210.200 1111,8631 4,999 1.371,218 1111,8631 161.018 Totsl 161.018 1.103.336 1.264.354 Analysls of net assets beiween fund5. woor year R•strlctod Unr•strfctsd funds funds 2022 2022 Total funds 2022 Tangible ffix8d assgts Current assets Cr&Jitors dl wilhin one year 7.033 7.033 {16.4011 1,455.609 1.439.208 1270.7211 (270.7211 Total 116.4011 1.191.921 1,175.520 P•)e 30
Oootsiyn En%*b)pe ID. C6B5cC(U1F74F9&85cF895SlD957 FOLLICULAR LYMPHOMA FOUNDATION (A company Ilmitèd by guaramts•l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 17. RKon¢iliation of not mov•m•nt In fvnds to n•t cash Ilow from operating activitie$ 2023 2022 Net incom81expeThYiture for thè year {a$ per Ststemwt of FinanLial Actimtiesl 88.834 (223,9351 AdJustm•nts lor. Depreciation charges Intorest received (Increydeease detAS Increase1(deasel in CJit(S 2.482 16,419 126,080 1142,4571 3,263 11,6191 134,9921 206.81)0 N•1 cash us•d In OP•fating activities 183.6401 148.453) 18. An•ty$i$ ol cash and cash 8qulval•nts 2023 2022 Cash in han(J Deficit in restn.cted r&seThe 1.287.372 1.381,442 116,401) Total cash and ¥h equivalonts 1,287,372 1,365,041 ' 19. Analysls ol than9 In net debt At31 Oecember 2023 January 2023 Cash flows Cash at bank and in hand Oebt due Wit. l year 1.381.442 (17,251) 194,070) 1,287,372 15.671 11,5801 1.364,191 178.3991 1.285,792 Page 31
tk)¢¥gw Env4¢p¢ ID. C6P5CI)O&81F74F9842cF89s5ll57 . FOLUCULAR LYMPHOAIA FOUNDATION . IA MpanY Ilmtt•d by guarant•e) NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2023 20. . Members. liabllity The charitsble company is limited by guarantee * has no $hare capital. in the event of the charilable company ng w(4Jn(kup. the liat41ity in respeL1 of the guaranlee is limited to £10 per member of tho ¢haritsbSe company durin9 the time they are a mèmber or wthin one year of ceasing lo be a rnember. as ststed in the Memorandum and AJ1ides of Assotiati"¢)n. 21. Related party tran5a¢ti¢)n$ The We no lurtW related paty transathons other than the trustees. donations disdosed in note 10 f(* Ihe ye8f ended 31 December 2023. Page 32